Perioperative high-dose-rate brachytherapy (PHDRB) in previously irradiated head and neck cancer: Initial results of a Phase I/II reirradiation study
- PMID: 16563995
- DOI: 10.1016/j.brachy.2005.11.003
Perioperative high-dose-rate brachytherapy (PHDRB) in previously irradiated head and neck cancer: Initial results of a Phase I/II reirradiation study
Abstract
Background: This study was undertaken to determine the feasibility of salvage surgery and perioperative high-dose-rate brachytherapy (PHDRB) at the dose/fractionation schedule proposed in patients with previously irradiated, recurrent head and neck cancer or second primary tumors arising in a previously irradiated field.
Methods and materials: Twenty-five patients were treated with surgical resection and PHDRB. The PHDRB dose was 4 Gy b.i.d. x 8 (32 Gy) for R0 resections and 4 Gy b.i.d. x 10 (40 Gy) for R1 resections. Further external beam radiotherapy or chemotherapy was not given.
Results: Resections were categorized as R0 (negative margins of at least 10 mm) in 3 patients (12.0%) and R1 (negative margins of less than 10 mm or microscopically positive margins) in 22 (88.0%). Twelve patients with R1 resections had microscopically positive margins (48%), and 10 patients had close margins (40%), with a median of 2.0 mm. Ten patients (40.0%) developed Radiation Therapy Oncology Group Grade 3 or greater toxicity. Seven patients (28%) presented complications requiring a major surgical procedure. Four of these complications appeared in the immediate postoperative period and were surgical in nature (flap failure, n = 2; fistula, n = 2), and the other three were mainly related to the brachytherapy procedure (n = 2) or the radiation dose delivered (n = 1). One patient died on postoperative day 11 due to bleeding. After a median followup of 14 months, the 4-year local control rate and overall survival were 85.6% and 46.4%, respectively.
Conclusions: Surgical salvage and PHDRB at the dose/fractionation proposed are feasible in this high-risk population. Toxicity is high, but not substantially different from other reirradiation series. Four-year local control results are encouraging taking into account that 22 of 25 patients (88%) had either close or microscopically positive margins.
Similar articles
-
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18. Int J Radiat Oncol Biol Phys. 2006. PMID: 16414206 Clinical Trial.
-
Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecologic cancer: Initial results of a phase II trial.Brachytherapy. 2006 Oct-Dec;5(4):203-10. doi: 10.1016/j.brachy.2006.07.001. Brachytherapy. 2006. PMID: 17118310 Clinical Trial.
-
Phase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer.Brachytherapy. 2009 Jan-Mar;8(1):26-33. doi: 10.1016/j.brachy.2008.10.002. Epub 2008 Nov 28. Brachytherapy. 2009. PMID: 19041280 Clinical Trial.
-
High-dose-rate brachytherapy in the treatment of recurrent and residual head and neck cancer.Laryngoscope. 2002 Aug;112(8 Pt 1):1366-71. doi: 10.1097/00005537-200208000-00008. Laryngoscope. 2002. PMID: 12172246 Review.
-
[Brachytherapy for head and neck cancers (nasopharynx excluded)].Cancer Radiother. 2008 Nov;12(6-7):515-21. doi: 10.1016/j.canrad.2008.08.276. Epub 2008 Sep 27. Cancer Radiother. 2008. PMID: 18824384 Review. French.
Cited by
-
Radiation responses in skin and connective tissues: effect on wound healing and surgical outcome.Hernia. 2006 Dec;10(6):502-6. doi: 10.1007/s10029-006-0150-y. Hernia. 2006. PMID: 17047884 Review.
-
Local Control, Survival, and Toxicity Outcomes with High-Dose-Rate Peri-Operative Interventional Radiotherapy (Brachytherapy) in Head and Neck Cancers: A Systematic Review.J Pers Med. 2024 Aug 11;14(8):853. doi: 10.3390/jpm14080853. J Pers Med. 2024. PMID: 39202044 Free PMC article. Review.
-
Interventional radiotherapy (brachytherapy) for re-irradiation of recurrent head and neck malignancies: oncologic outcomes and morbidity.Acta Otorhinolaryngol Ital. 2024 May;44(Suppl. 1):S28-S36. doi: 10.14639/0392-100X-suppl.1-44-2024-N2824. Acta Otorhinolaryngol Ital. 2024. PMID: 38745514 Free PMC article.
-
Pilot Evaluation of Perioperative High Dose Rate Brachytherapy in Head Neck Cancers.Indian J Otolaryngol Head Neck Surg. 2024 Apr;76(2):2166-2170. doi: 10.1007/s12070-023-04455-0. Epub 2024 Jan 8. Indian J Otolaryngol Head Neck Surg. 2024. PMID: 38566724 Free PMC article.
-
Head and neck (192)Ir HDR-brachytherapy dosimetry using a grid-based Boltzmann solver.J Contemp Brachytherapy. 2013 Dec;5(4):232-5. doi: 10.5114/jcb.2013.39444. Epub 2013 Dec 18. J Contemp Brachytherapy. 2013. PMID: 24474973 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical